Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.5%) at 16,493 as of Tuesday, Aug. 5, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,020 issues advancing vs. 1,966 declining with 149 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.6%. A company within the industry that increased today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.4%. On the negative front, top decliners within the industry include Ironwood Pharmaceuticals ( IRWD), down 7.6%, Health Net ( HNT), down 3.4%, Grifols ( GRFS), down 2.5%, UnitedHealth Group ( UNH), down 1.4% and Humana ( HUM), down 0.7%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Edwards Lifesciences ( EW) is one of the companies pushing the Health Services industry higher today. As of noon trading, Edwards Lifesciences is up $1.17 (1.2%) to $94.57 on average volume. Thus far, 483,780 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $93.20-$94.71 after having opened the day at $93.53 as compared to the previous trading day's close of $93.40. Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $9.7 billion and is part of the health care sector. Shares are up 42.0% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Edwards Lifesciences Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.